© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Experts collaborate on 3 patient scenarios to review the current treatment paradigm of graft versus host disease in the context of key clinical trial data.
March 31st 2022
Expert perspectives on the nature and occurrence of graft-versus-host disease alongside available prophylactic regimens.
April 1st 2022
Centering discussion on a patient scenario of acute graft-versus-host disease, participants discuss nuance in disease symptomology and patient education.
A panel of experts discuss systemic therapy to manage a patient with acute graft-versus-host disease.
Experts review the prognosis of a patient with acute graft-versus-host disease and identify ways to optimize their treatment strategies.
April 4th 2022
Shifting their focus to chronic graft-versus-host disease, experts review a patient scenario and discuss the challenges in early intervention.
Shared insight on how to distinguish chronic GVHD from acute GVHD, as well as utilize appropriate methods to risk stratify disease.
A review of treatment options approved for steroid-refractory chronic graft-versus-host disease starting with ibrutinib and ruxolitinib.
Considerations for belumosudil and axatilimab as treatment options for steroid-refractory chronic graft-versus-host disease.
Having reviewed approved treatment options for steroid-refractory, chronic GVHD, experts discuss how they would address this patient scenario.
A brief discussion on the risk of treatment-induced damage when managing patients with chronic graft-versus-host disease.